Back to search
FDAFDA · Food and drugs·Recall number Z-2202-2017

H. pylori (polyclonal} 1.0 mL Catalog number 215A-76; Hematology - Analyte Specific Reagent In vitro diagnostic use - Analyte Specific Reagent

Published June 7, 2017 · Recall initiated: May 5, 2017

Summary

FDA records medical device Class II recall Z-2202-2017, published June 7, 2017 and initiated May 5, 2017. Recalling firm: Cell Marque Corporation; Status: Terminated; Reported quantity: 5; Lot: 1.0 ml lot 1611307C, expiry 201 9-03. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Cell Marque has determined the need to issue a product recall after identifying product intended to be sold outside the U.S. was not properly labeled as "For Export Only" as required by section 801 (e )(1) of the FD&C Act.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Cell Marque Corporation
Distributor
Nationwide Distribution to CA, CO, DE, FL, GA, IL, KY, MD, MA, MS, NJ, NY, NC, OH, OK, OR, PA, TX.
Lot
1.0 ml lot 1611307C, expiry 201 9-03.
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was H. pylori (polyclonal} 1.0 mL Catalog number 215A-76; Hematology - Analyte Specific Reagent In vitro diagnostic use - Analyte Specific Reagent recalled?

Yes. FDA published recall Z-2202-2017 on June 7, 2017. Reported hazard: Cell Marque has determined the need to issue a product recall after identifying product intended to be sold outside the U.S. was not properly labeled as "For Export Only" as required by section 801 (e )(1) of the FD&C Act.

What should I do if I have this product?

Voluntary: Firm initiated · Letter